TUDCA 100x500mg

NOT FOR HUMAN CONSUMPTION

TUDCA is the taurine-conjugated form of ursodeoxycholic acid (UDCA), a hydrophilic, cytoprotective bile acid that acts as a chemical chaperone to relieve endoplasmic-reticulum (ER) stress, stabilizes mitochondria (anti-apoptotic), and modulates bile-acid receptors (notably TGR5; very weak FXR activity). Clinically, UDCA is widely used for cholestatic liver disease; TUDCA is available as a drug in some countries and as a supplement in others. Interest spans liver, metabolic, neurologic, and ocular indications.

Additional Benefits of TUDCA Now Under Investigation

2. Molecular Mechanism of Action

2.1 Pharmacodynamics

• ER-stress “chemical chaperone”: TUDCA stabilizes protein folding, normalizes the unfolded-protein response (UPR) (PERK/eIF2α, IRE1/XBP1, ATF6), and reduces CHOP-mediated apoptosis.

• Mitochondrial protection: Inhibits Bax activation/translocation, preserves ΔΨm, reduces ROS, and limits caspase-9/3 activation.

• Bile-acid signaling: Predominantly TGR5 agonism (↑ cAMP; GLP-1 and energy-expenditure signals in some tissues); minimal FXR agonism compared with chenodeoxycholic acid/obeticholic acid.

• Membrane/cytoprotection: Renders the bile-acid pool more hydrophilic, reducing detergent injury to hepatocytes/cholangiocytes.

2.2 Down-stream Biology

3. Pharmacokinetics

• Route: Oral (capsules, tablets); also IV in some research settings.

• Absorption: Variable; enhanced with food; undergoes enterohepatic recirculation.

• Distribution: Concentrates in bile and liver; modest CNS penetration reported.

• Metabolism: Bile-salt transporters mediate cycling; intestinal deconjugation/reconjugation by microbiota.

• Half-life: Several hours with multi-peak profile due to recirculation; functional exposure persists with divided dosing.

4. Clinical Evidence (high-level)

• NAFLD/MASH: Small RCTs/controlled studies show enzyme and fat-fraction improvements; histologic endpoints remain limited vs lifestyle/GLP-1 class.

• Cholestatic disease: Strongest human evidence still favors UDCA as standard; TUDCA provides mechanistic overlap and is used regionally; head-to-head outcome superiority is unproven.

• Type 2 diabetes/IR: Proof-of-concept studies demonstrate improved insulin sensitivity (clamp data) and inflammatory/oxidative markers.

• Neuro: ALS/PD/HD trials show signals (slower functional decline/biomarkers) but mixed outcomes in larger programs; research continues (including combinations).

• Eye: Human data are early; robust animal protection against photoreceptor death.

Evidence quality note: Solid mechanistic and translational base; moderate human evidence for metabolic and hepatobiliary endpoints; emerging/variable in neuro/ocular fields.

5. Practical Use (research & real-world patterns)

• Doses used in studies: 250–1,500 mg/day, often 10–15 mg/kg/day in divided doses with meals.

• Use cases (off-label/supplement): NAFLD/MASH adjunct, metabolic syndrome/IR, cholestatic tendencies, “neuro-support” (investigational).

• Stacking considerations:

  • Liver/metabolic: Diet + exercise, weight-loss pharmacotherapy if indicated; vitamin D, omega-3; avoid hepatotoxins.

  • Neuro: Antioxidants/mitochondrial supports are investigational; avoid claims beyond evidence.

6. Safety and Tolerability

• Common: GI upset, soft stools/diarrhea, mild nausea; usually dose-related and improved with food/split dosing.

• Less common: Pruritus, headache, flatulence.

• Rare/uncertain: Biliary colic in gallstone formers (theoretic), rash.

• Drug interactions: May interact with bile-acid sequestrants (reduced absorption, separate by ≥4 h). Monitor with warfarin if large liver-function shifts occur.

• Special populations: Pregnancy, UDCA is standard for intrahepatic cholestasis of pregnancy; specific TUDCAdata are more limited, defer to local guidance.

• Long-term safety: Generally favorable in published series; monitor LFTs, lipids, and glycaemia in metabolic indications.

Comparative matrix (bile-acid & adjunct options)

7. Regulatory Landscape

• Status: UDCA is widely approved; TUDCA is approved in some regions and sold as dietary supplement in others (quality varies).

• Indications: Vary by country; many uses (NAFLD, neuro, ocular) remain off-label/investigational.

• Quality note: If using supplement routes, prefer GMP-certified suppliers with third-party testing.

8. Future Directions

• Head-to-head trials: TUDCA vs UDCA in cholestasis; combination with GLP-1/GIP agents in MASH.

• Biomarker-guided therapy: ER-stress signatures, bile-acidomics, and MRI-PDFF/MRE endpoints.

• Neuro trials: Larger, longer ALS/PD studies; combination regimens (mitochondrial/anti-excitotoxic).

• Formulation science: Enteric-coated and controlled-release to optimize delivery and reduce GI effects.

• Microbiome synergy: Pairing with pre/probiotics to stabilize bile-acid pools and intestinal barrier.

Selected References

• Hepatology; Journal of Hepatology; Liver International, TUDCA/UDCA in NAFLD and cholestasis; enzyme and imaging outcomes.

• Diabetes; Journal of Clinical Endocrinology & Metabolism, Human insulin-sensitivity improvements and mechanistic signaling.

• Neurology; Annals of Neurology; Movement Disorders, ALS/PD/HD trials and biomarker studies with tauroursodeoxycholic acid.

• Investigative Ophthalmology & Visual Science; Experimental Eye Research, Retinal protection and photoreceptor survival.

• Gut; Gastroenterology, Bile-acid–microbiome interactions, intestinal barrier effects.

• Cell Death & Disease; Journal of Physiology, ER-stress, mitochondrial, and anti-apoptotic mechanisms.

• Alimentary Pharmacology & Therapeutics, Clinical use patterns and tolerability in hepatobiliary disease.

• Obesity Surgery; Metabolism, Post-bariatric metabolic/bile-acid changes and TUDCA adjunction.